---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003459"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:18:17.287909+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Vor Biopharma updates investor presentation; no material new information disclosed

## Summary
- Filed an updated corporate presentation under Item 8.01 on January 5, 2024.
- Presentation reiterates ambition to cure blood cancers via cell and genome engineering.
- No financial results, guidance, clinical data, or strategic updates were provided.
- Exhibit 99.1 includes only a title slide; full content was not disclosed in the filing.
- The update appears routine with no new business developments.

## SEC filing metadata
- accession: 0001193125-24-003459
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312524003459/0001193125-24-003459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312524003459/d703283d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003459
- JSON: https://secwatch.observer/filing/0001193125-24-003459.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003459.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.